Bicara plans Q3 alternative dosing study of ~150-200 patients as it targets mid-2027 interim analysis
Source: SeekingAlpha
2026-05-11 12:01:42 ET
More on Bicara Therapeutics
- Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call Transcript
- Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement
- Bicara Therapeutics Inc. (BCAX) Q4 2025 Earnings Call Transcript
- Bicara Therapeutics GAAP EPS of -$0.93 misses by $0.28
- Bicara Therapeutics GAAP EPS of -$0.68
Read the full article on Seeking Alpha
For further details see:
Bicara plans Q3 alternative dosing study of ~150–200 patients as it targets mid-2027 interim analysis
Bicara Therapeutics Inc.
NASDAQ: BCAX
BCAX Trading
-1.34% G/L:
$20.21 Last:
94,008 Volume:
$20.28 Open:
BCAX Latest News
May 21, 2026 05:00:00 pm
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-? Inhibition in 1L R/M HPV-Negative HNSCC
May 15, 2026 07:02:41 pm
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
May 13, 2026 08:30:00 am
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BCAX Stock Data
$817,548,781
24,302,552
0.5%
33
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
